Competitive Intelligence
1. Competitive landscape snapshot (week ending August 16)
Ozempic appears in a crowded but highly concentrated comparison set. Wegovy leads with 45 mentions, followed by Mounjaro (24) and Trulicity (22). Secondary names are Zepbound (11), Rybelsus (10), Victoza (8), Saxenda (6), Bydureon (2), and Byetta (1)—143 competitor mentions in total.
At least 38 mentions come from explicitly named comparative questions: Trulicity appears in the six-response “more effective than Trulicity” question and the seven-response label comparison; Mounjaro appears in the six-response switching question and seven-response label comparison; Wegovy and Rybelsus each appear in six-response direct comparisons. The balance is largely incidental or contextual—especially in answers about alternatives, indications, dosing, and Ozempic’s broader online visibility. Wegovy’s 45 mentions therefore reflect both direct comparison and its role as the default weight-management counterpart.
2. How the comparison is currently framed
- Wegovy — mostly neutral, with clear category separation. AI consistently frames the products as sharing semaglutide but serving different positioning: Ozempic is associated with type 2 diabetes, while Wegovy is described as the dedicated weight-management product. Typical language says they are “closely related but not exactly the same product,” with different dosing and indications. This gives Wegovy a clearer weight-loss role without broadly displacing Ozempic.
- Trulicity — generally favors Ozempic. All six responses to the direct effectiveness question say Ozempic is perceived as more effective, particularly for weight loss and often glucose lowering, and that this is “not purely marketing” or is “grounded in clinical trial results.” All six also carry
overclaim_language, including “stronger,” “best,” “superior,” or “leading.” The framing is directionally favorable to Ozempic, though usually qualified by endpoint and patient variability. - Mounjaro — balanced mechanism comparison, but with a competitor-strength signal. Responses consistently explain Mounjaro’s dual GIP/GLP-1 mechanism versus Ozempic’s GLP-1-only mechanism. Five to six responses use language such as “stronger,” and one says dual action can produce “similar or sometimes greater effects,” creating a recurring implied advantage for Mounjaro despite hedging.
- Rybelsus — largely neutral and formulation-led. Answers emphasize shared semaglutide and overlapping warnings, with the main distinction being oral versus injectable administration.
3. Movers — who’s gaining or losing ground
All named competitors declined week over week, alongside a 7% reduction in total responses:
- Wegovy: 45, down 1
- Mounjaro: 24, down 2
- Trulicity: 22, down 3
- Zepbound: 11, down 1
- Rybelsus: 10, down 1
- Victoza: 8, down 2
- Saxenda: 6, down 6
- Bydureon: 2, down 3
- Byetta: 1, down 3
No new entrant appeared. Over the six-week history, Wegovy remains the leading and most durable comparator, while Mounjaro and Trulicity have also expanded materially from July 12 (+16 each in raw mentions). This week looks like normalization after a higher-volume prior week, not a competitive reversal.
4. Questions worth watching
- “Do people typically perceive Ozempic as more effective than Trulicity…?”
- “If someone switches from Ozempic to Mounjaro…what differences…are described?”
- “What’s the difference between Ozempic and Wegovy…?”
- “Compared with Trulicity or Mounjaro, what outcomes…are supported by Ozempic’s labeling?”
5. Recommended actions
- Continue routine monitoring: no competitor gained raw mention share this week.
- Track Mounjaro specifically: its persistent mechanism-and-strength framing warrants watching for sustained competitor-favoring language.
- Flag the Trulicity comparison to the brand team: six direct answers favor Ozempic, with repeated superiority wording.
- Maintain a Wegovy comparison watch: 45 mentions confirm it remains Ozempic’s primary AI-defined counterpart, especially around weight management.